Merck still sees ‘compelling’ outlook for Terns leukemia drug
BioPharma Dive
Despite updated study data that suggest Terns treatment may be less differentiated, company executives claimed Thursday that it still could be an important step forward in care.
pharminent
April 30, 2026 (Last updated: May 1, 2026)
BioPharma Dive
Despite updated study data that suggest Terns treatment may be less differentiated, company executives claimed Thursday that it still could be an important step forward in care.
